ATE175348T1 - L - deprenyl zur behandlung von makulärer degeneration - Google Patents

L - deprenyl zur behandlung von makulärer degeneration

Info

Publication number
ATE175348T1
ATE175348T1 AT93909617T AT93909617T ATE175348T1 AT E175348 T1 ATE175348 T1 AT E175348T1 AT 93909617 T AT93909617 T AT 93909617T AT 93909617 T AT93909617 T AT 93909617T AT E175348 T1 ATE175348 T1 AT E175348T1
Authority
AT
Austria
Prior art keywords
deprenyl
macular degeneration
treatment
disease
ameliorate
Prior art date
Application number
AT93909617T
Other languages
English (en)
Inventor
Hastings Barbara A Fries
Original Assignee
Somerset Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somerset Pharmaceuticals Inc filed Critical Somerset Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE175348T1 publication Critical patent/ATE175348T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Semiconductor Lasers (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT93909617T 1992-04-23 1993-04-23 L - deprenyl zur behandlung von makulärer degeneration ATE175348T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/872,839 US5242950A (en) 1992-04-23 1992-04-23 Treatment of macular degeneration

Publications (1)

Publication Number Publication Date
ATE175348T1 true ATE175348T1 (de) 1999-01-15

Family

ID=25360402

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93909617T ATE175348T1 (de) 1992-04-23 1993-04-23 L - deprenyl zur behandlung von makulärer degeneration

Country Status (14)

Country Link
US (1) US5242950A (de)
EP (1) EP0637238B1 (de)
JP (1) JP2669721B2 (de)
AT (1) ATE175348T1 (de)
AU (1) AU679679B2 (de)
BR (1) BR9306283A (de)
CA (1) CA2133998C (de)
DE (1) DE69322957T2 (de)
DK (1) DK0637238T3 (de)
ES (1) ES2127819T3 (de)
GR (1) GR3029670T3 (de)
HU (1) HU224917B1 (de)
NO (1) NO944018D0 (de)
WO (1) WO1993021894A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US5783606A (en) * 1995-02-10 1998-07-21 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
CA2212412A1 (en) 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
NZ309980A (en) 1995-06-07 2001-06-29 Noven Pharma Transdermal composition containing a blend of one or more polymers, one or more drugs that has a low molecular weight and is liquid at room temperature
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5827652A (en) 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
AU707646B2 (en) * 1995-11-06 1999-07-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
WO1999047133A1 (en) 1998-03-16 1999-09-23 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
US7691406B2 (en) * 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
ATE427745T1 (de) 2001-11-05 2009-04-15 Krele Pharmaceuticals Llc Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
CA2505476C (en) * 2002-11-07 2015-05-26 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20040180090A1 (en) * 2003-03-12 2004-09-16 Demarco Peter Treatment of macular degeneration
CA2523567A1 (en) * 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Method for promoting uninterrupted sleep by administration of trospium chloride
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
WO2005051371A1 (en) * 2003-11-25 2005-06-09 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
EP3381446A1 (de) 2004-10-29 2018-10-03 The Regents of The University of California Poröse photonische kristalle zur verabreichung von wirkstoffen ins auge
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
MX2009000792A (es) * 2006-07-28 2009-02-03 Alcon Res Ltd Inhibidores de monoamina oxidasa utiles para tratar trastornos de la retina externa.
CN101815504B (zh) 2007-07-10 2013-11-20 加利福尼亚大学董事会 用于向所选择组织递送组合物的材料和方法
WO2011095973A1 (en) 2010-02-03 2011-08-11 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
CA2990247C (en) 2015-07-09 2023-10-03 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4868218A (en) * 1987-08-18 1989-09-19 Buyske Donald A Method of treating depression
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same

Also Published As

Publication number Publication date
NO944018L (no) 1994-10-21
DE69322957D1 (de) 1999-02-18
JPH07505906A (ja) 1995-06-29
DK0637238T3 (da) 1999-08-30
WO1993021894A2 (en) 1993-11-11
AU679679B2 (en) 1997-07-10
NO944018D0 (no) 1994-10-21
HUT72295A (en) 1996-04-29
EP0637238A1 (de) 1995-02-08
CA2133998C (en) 2006-03-21
GR3029670T3 (en) 1999-06-30
JP2669721B2 (ja) 1997-10-29
CA2133998A1 (en) 1993-11-11
AU4033993A (en) 1993-11-29
HU224917B1 (en) 2006-04-28
EP0637238B1 (de) 1999-01-07
US5242950A (en) 1993-09-07
BR9306283A (pt) 1998-06-30
WO1993021894A3 (en) 1994-01-20
ES2127819T3 (es) 1999-05-01
DE69322957T2 (de) 1999-07-01
HU9403052D0 (en) 1994-12-28

Similar Documents

Publication Publication Date Title
ATE175348T1 (de) L - deprenyl zur behandlung von makulärer degeneration
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ATE71629T1 (de) Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels.
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE179888T1 (de) Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69206607D1 (de) Behandlung von kognitiven störungen.
DE69833727D1 (de) Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
RU93046326A (ru) Способ лечения медикаментозных эзофаго-гингиво-стоматитов
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
DE69214647D1 (de) Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
RU1821745C (en) Method for prognosticating effectiveness of efferent therapeutic treatment of patients suffering from immunocomplex diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee